Project 1: Investigating the role of PBF in the nucleus and nucleolus and Project 2: An investigation into the role of adiposity on colorectal tumourigenesis by Poole, Vikki Louise
 
 
Project 1 - INVESTIGATING THE ROLE OF PBF IN THE NUCLEUS AND 
NUCLEOLUS 
 
AND 
 
Project 2 - AN INVESTIGATION INTO THE ROLE OF ADIPOSITY ON 
COLORECTAL TUMOURIGENESIS 
 
By 
 
VIKKI LOUISE POOLE 
 
 
THIS PROJECT IS SUBMITTED IN PARTIAL FULFILMENT OF THE 
REQUIREMENTS FOR THE AWARD OF THE MRES 
 
College of Medical and Dental Sciences 
University of Birmingham 
August 2012 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third parties. 
The intellectual property rights of the author or third parties in respect of this work 
are as defined by The Copyright Designs and Patents Act 1988 or as modified by 
any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission of 
the copyright holder.  
 
 
 
 Overall Contents 
 
Project 1            1 
- Title            1  
- Abstract           2 
- Introduction          7 
- Methods and Materials       15 
- Results         19 
- Discussion         32 
- Appendices         36 
- References         39 
 
 
Project 2          42 
- Title          42 
- Abstract         43 
- Introduction        51 
- Methods and Materials       59 
- Results         68 
- Discussion         88 
- Appendices         94 
- References         96 
 
 
 
 
 
  
INVESTIGATING THE ROLE OF PBF IN THE NUCLEUS AND NUCLEOLUS 
 
 
By 
 
VIKKI LOUISE POOLE 
 
 
 
THIS PROJECT IS SUBMITTED IN PARTIAL FULFILMENT OF THE 
REQUIREMENTS FOR THE AWARD OF THE MRES 
 
 
College of Medical and Dental Sciences 
University of Birmingham 
August 2012 
 
 
 Abstract 
Pituitary tumour transforming gene (PTTG) binding factor (PBF or PTTG1IP), is a poorly characterised 
protein found to be upregulated in thyroid cancer. The protein has previously been determined to 
contain several predicted signal sequences within its 180 amino acids, and previous studies have 
shown the nuclear localisation signal (NLS) to be functional. However, it is unknown whether the 
predicted nuclear export signal (NES) is functional. Use of nuclear/cytoplasmic fractionation and 
immunofluorescence, in this study, established that when PBF is C-terminally tagged with 
haemagglutinin (HA), PBF can no longer translocate to the nucleus, implying that the HA tag 
interferes with recognition of the NLS. The study also attempted to determine functionality of the 
predicted NES. Homology data revealed the NES is not conserved among six other mammalian 
species, suggesting it is not evolutionary important and therefore may not functional; however, when 
exportin-1 (CRM1) was inhibited/knockdowned in vitro, immunofluorescence revealed reduced 
cytoplasmic and nucleolar PBF staining, suggesting the NES may, in fact, have a role in Homo sapiens. 
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Introduction 
The Thyroid Gland 
The thyroid gland is a highly vascularised organ, found in the neck, which acts as one of the body’s 
largest endocrine organs (Figure 1).  The gland is comprised of large follicles in which iodide is 
concentrated; this iodide is then used in the production of the hormones thyroxine (T4) and 
triiodothyronine (T3), which are key regulators of metabolism and development. 
  
 
 Figure 1– The anatomy of the thyroid gland– Taken from Mayo Clinic 2012 
Diseases of the thyroid are relatively common and have been shown to affect approximately 5–10% of 
the population (Hunt and Wass, 2001). Thyroid cancer is the most common form of endocrine cancer, 
with an incidence rate that has doubled within the past 30 years; however there has been shown to be a 
significant correlation between increased incidence and both increased and earlier detection rates 
(Grodski et al., 2008). There are four major types of thyroid cancers (papillary, follicular, medullary and 
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anaplastic), which are classified by their different histopathologies (National Cancer Institute, 2012).  
Papillary thyroid cancer (PTC) is the most common form, representing 60% of all thyroid carcinomas, 
however the prognosis is relatively good with about 90% of cases having a 10 year cancer-free survival 
rate (CRUK, 2011).  The main treatment for thyroid carcinomas is surgical resection of the thyroid, 
followed by radioiodide treatment to ablate any residual thyroid tissue (Alford et al., 2011).  There are 
several risk factors for the development of thyroid neoplasms including family history of endocrine 
malignancy, ionising radiation, and being of the female sex (Grodski et al., 2008). However, despite 
research into oncogenes such as BRAF and RAS, the mechanisms that lead to the development of 
thyroid carcinoma are yet to be fully understood. Recent research has indicated that PBF, a little 
characterised proto-oncogene, may be involved in the aetiology of the disease. 
 
PBF 
Pituitary tumor-transforming gene (PTTG) binding factor (PBF), also known as pituitary tumor-
transforming gene 1 protein-interacting protein (PTTG1IP), is a 22kDa protein made up of 180 amino-
acids. The protein is highly conserved among a variety of species (73% homology to mouse, 67% frog, 
60% chicken) yet it shares no homology with other human proteins (Read et al., 2011). The protein was 
first described in 2000 by Chien & Pei who, through a yeast two-hybrid screen, discovered its capability 
to interact with PTTG, a human securin (Chien and Pei, 2000). Since its identification, it has only been 
described in 14 publications.  Although PBF was not formally identified until 2000, it had previously been 
cloned and termed C21orf3 by Yaspo et al in 1998, who located the then unknown protein on 
chromosome 21q22.3. Initial predictive studies suggested that C21orf3 may be a cell surface 
glycoprotein important in cell trafficking mechanisms, as it contained a potential N-terminal signal 
peptide, a transmembrane domain, an endocytosis motif and N-glycosylation sites (Yaspo et al., 1998). 
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Subsequent studies have since shown that PBF contains a nuclear localisation signal (NLS), suggesting 
that it has a role in both the cytoplasm and as a nuclear protein (Chien and Pei, 2000) (Figure 2). 
 
 
Figure 2 – Structure of Wildtype PBF – PBF contains several different domains and signals, these include 
an N-terminal signal peptide, containing the proposed nuclear export signal (NES), a PSI (plexin-
semaphorin-integrin) domain, a transmembrane region which is then followed by a predicted nucleolus 
location signal (NoLS), nuclear localisation signal (NLS) and a C-terminal sorting signal. PBF also contains 
a sumoylation site along with several phosphorylation sites. 
 
Although PBF’s function is yet to be fully characterised, studies have shown it is ubiquitously expressed 
throughout normal human tissue. In 2003, the protein was shown to be upregulated in pituitary 
adenomas (McCabe et al., 2003); later studies have also shown increased levels in cancers such as breast 
(Watkins et al., 2010) and thyroid (Stratford et al., 2005). In well differentiated thyroid cancers, such as 
papillary and follicular, PBF expression has been shown to be significantly increased compared to levels 
in normal thyroid tissue, and to be an indicator of cancer recurrence. Although PBF is upregulated in 
these diseases, no associated mutations within the protein have been found (Stratford et al., 2005); 
however, a recent genomic study of ovarian carcinomas uncovered one patient sample containing a 
Signal peptide PSI Domain
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mutation in PBF, in the protein’s transmembrane region, suggesting PBF may have a role in a wider 
variety of cancers (Network, 2011).  
Although PBF’s function is generally poorly characterised, a role for it in thyroid cancer, the 
disease in which PBF has primarily been studied, has been established. In the thyroid, the sodium iodide 
symporter (NIS) is responsible for transporting iodide into the thyroid follicles, where it accumulates 
prior to synthesis of thyroid hormones. In thyroid follicular epithelial cells, NIS is usually found at the 
plasma membrane, allowing the transport of ions into and out of the cell. However, in thyroid cancers, 
increased PBF levels have correlated with the internalisation of NIS, therefore inhibiting iodide uptake. 
This is particularly important in the context of radioiodide treatment and imaging, which is used in 
diagnosing and treating the disease (Smith et al., 2009). PBF has also recently been shown to interact 
with and regulate p53, a protein associated with 50% of cancers (Read et al., 2012). 
As the nature of PBF appears to have different roles in cancer, it is important to establish the 
protein’s function, as this will provide an increased understanding of its therapeutic potential. An insight 
into function frequently results from establishment of the location of a protein within the cell, as this 
allows the identification of proteins and organelles with which the protein may interact. Proteins often 
contain localisation signals within their amino acid sequences, these signals acting like post-codes 
allowing the protein to be sent to the right ‘address’ or subcellular compartment and therefore 
providing a useful approach to predicting  the potential location of proteins. 
 
 
 
Signal Sequences 
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First discovered in the early 1970s, localisation signals (known also as signal sequences) have been 
identified that direct proteins to various cellular compartments such as the nucleus, mitochondria and 
endoplasmic reticulum. It is accepted within the field that PBF contains a functional C-terminal nuclear 
localisation signal, which allows the protein to be transported into the nucleus. NLS usually consist of a 
short sequence of basic amino acids (lysines and arginines) exposed on the protein’s surfaces. PBF 
contains a bipartite NLS between amino acids 149-166, containing several arginines and lysines (Chien 
and Pei, 2000). Along with signals to enter the nucleus, there is also a sequence known as the nuclear 
export signal (NES), allowing proteins to be transported out of the nucleus. This signal is usually a series 
of four hydrophobic residues in a protein that are ‘recognised’ and bound to by exportins, which then 
facilitate transport of the protein from the nucleus (La Cour et al., 2004). The amino acid sequence of 
PBF has previously been submitted to prediction software (CBS Prediction Servers) which showed PBF to 
have a predicted NES between amino acids 17-27, compromising of a run of hydrophobic leucines 
(unpublished) (Figure 3A). Although the software predicted the NES to be present, it is unknown 
whether the sequence is actually functional. PBF has also been shown to have a nucleolus localisation 
site (NoLS) using prediction software (NOD – Nucleolar localisation sequence detector (University of 
Dundee) (Figure 3B). These signals are useful tools in both determining the location of PBF, and 
identifying potential proteins PBF may interact with. For example, if the NES in PBF is truly functional, it 
is highly likely that PBF interacts with the protein exportin-1. 
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Figure 3 – Predicted Signal Sequences 
3A – NES Prediction in PBF – The amino acid sequence of PBF was entered into CBS Prediction Server. 
The software predicted PBF to have an NES between amino acids 17-27. The pink line represents the 
threshold which, if the red NES score line crosses, suggests there is likely to be an NES. 
3B – NoLS Prediction in PBF – The amino acid sequence of PBF was entered into nucleolar localisation 
sequence detector software. The pink shaded area represents residues that are likely to be involved in a 
nucleolar location site. There is a predicted NoLS between residues 114 and 138. 
3C – Position of predicted NoLS and NES in PBF – The red represents the residues predicted to be 
involved in the potential NoLS site, whereas the green represent the predicted NES. 
A 
B 
Sequence of wild-type PBF (NoLS shown in red and NES in green):  
MAPGVARGPTPYWRLRLGGAALLLLLIPVAAAQEPPGAACSQNTNKTCEECL 
KNVSCLWCNTNKACLDYPVTSVLPPASLCKLSSARWGVCWVNFEALIITMSV 
VGGTLLLGIAICCCCCCRRKRSRKPDRSEEKAMREREERRIRQEERRAEMKT 
RHDEIRKKYGLFKEENPYARFENN 
C 
B 
A 
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Exportin-1 
Exportin-1, often referred to as CRM1 or XPO1, is the main protein responsible for exporting proteins 
containing leucine rich NES from the nucleus. When CRM1 was initially identified, its exact role was 
unclear, although it was believed to be essential in the maintenance of chromosome structure in fission 
yeast (Adachi and Yanagida, 1989). However, when genetic mutations were introduced to the CRM1 
locus in yeast, a defect in nuclear export of NES-bearing proteins was observed. Furthermore, when 
studied in vitro CRM1-specific antibodies were shown to prevent nuclear export in mammalian cells. 
These findings suggest that CRM1 is involved in a universal conserved mechanism for the export of 
proteins out of the nucleus (Kudo et al., 1999).  Studies have shown that in steady state CRM1 is located 
in the nucleus, but that it also has the ability to shuttle between the nucleus and the cytoplasm (Stade et 
al., 1997). CRM1 works by binding to its substrate (i.e. the protein being exported from the nucleus) and 
Ran-GTP, with this complex then being translocated through the nuclear pore complex (NPC) to the 
cytoplasm. Structural studies have shown that CRM1 is a ring-shaped protein that is capable of binding 
its substrates by their leucine rich NES, at the central convex surface. The leucine-rich helix of the 
substrate binds specifically into a hydrophobic groove created by helices of CRM1 HEAT repeats (Dong 
et al., 2009). Leptomycin B has been shown to inhibit CRM1 function by binding to cysteine 529 (Kudo et 
al., 1999), which is located in the hydrophobic groove, thereby blocking substrate binding (Dong et al., 
2009). 
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Hypothesis 
PBF has been found to contain a predictive NES; this study will try and determine whether the signal is 
functional and under the regulation of exportin-1. Recent laboratory observations have indicated that 
PBF is unable to enter the nucleus when it is C-terminally tagged with Human influenza hemagglutinin 
(HA). Therefore, before nuclear export can be studied, it is essential to formally identify if this tag blocks 
nuclear entry of PBF.          
 
Aims 
- To establish whether HA tagged PBF can enter the nucleus. 
- To delete the HA tag from the dual tagged PBF (FLAG-PBF-HA). 
- To mutate the predicted NES in PBF 
- To knockdown and inhibit CRM1 and observe its effect on the localisation of PBF in the cell.  
15 
 
Materials and Methods 
Cells culture and transfection 
K1 and TPC-1 cell lines were cultured in RPMI media supplemented with 10% (v/v) heat-inactivated 
foetal bovine serum (FBS), penicillin (105 U/l) and streptomycin (100 mg/l).Whereas Dulbecco's Modified 
Eagle Medium (DMEM) (Gibco) supplemented with 10% (v/v) heat-inactivated (FBS), penicillin (105 U/l) 
and streptomycin (100 mg/l) was used to culture HeLA and COS7 African Green monkey kidney 
epithelial cell lines. All cultures were incubated at 37⁰C and 5% CO2 in humidified conditions, being 
passaged twice weekly and discarded when the passage number became too high for efficient 
transfection. 
Transfection was carried out using Fugene 6 reagent (Roche, Indianapolis) at a 3:1 Fugene 
6:plasmid DNA ratio in Opti-MEM media. For protein extraction and immunofluorescence (IF) staining, 
cells were seeded in six-well plates (containing sterile coverslips for IF) and transfected with 2µg DNA 
plasmid after 24 hours. For nuclear/cytoplasmic extracts, cells were seeded in T25 flasks and transfected 
with 5µg DNA plasmid. The plasmids used in transfection were all in the pcDNA3 backbone and plasmids 
used included pcDNA3 vector only (VO), wild-type PBF, PBF-HA and mutant 1. Mutant 1 was selected as 
it lacks the amino acids 150-180, meaning there is no NLS; the protein is also HA-tagged at the C-
terminus. 
Mutagenesis 
Stratagene QuikChange Site-Directed Mutagenesis Kit (Agilent technologies) and Stratagene QuikChange 
II XL Site-Directed Mutagenesis Kit (Agilent technologies) were used for mutagenesis, following the 
manufacturer’s protocol. Wild-type PBF and PBF-HA plasmids were used to attempt to mutate the NES 
using the following primers: 
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Double mutation: 
Forward – 5’ GCC GTA CTG GAG GTT GCG CGC CGG TGG CGC CGC GGC GCT CCT GCT GCT CAT CCC G 3’ 
Reverse – 5’ C GGG ATG AGC AGC AGG AGC GCC GCG GCG CCA CCG GCG CGC AAC CTC CAG TAC GGC 3’ 
Single mutation: 
Forward –  5' G TAC TGG AGG TTG CGC GCC GGT GGC GCC GCG CTG 3' 
Reverse –  5' CAG CGC GGC GCC ACC GGC GCG CAA CCT CCA GTA C 3' 
The primers were designed following specifications given in the kit by the manufacturer and produced 
by Alta Bioscience, Birmingham UK. 
To remove the HA-tag from dual tagged PBF the following primers were used: 
Forward – 5’GCT AGA TTT GAA AAC AAC TAA TCT AGA GTC GAC CCG GGC GGC 3’ 
Reverse – 5’ GCC GCC CGG GTC GAC TCT AGA TTA GTT GTT TTC AAA TCT AGC 3’ 
From the colonies grown using the mutagenesis kit, 10 were selected and mini-prepped using Wizard 
Plus SV miniprep DNA purification system (Promega). The DNA was quantified using a 260/280 
NanoDrop-1000 spectrophotometer (NanoDrop). 100µg of DNA and 1µl T7 short primer dissolved in 
nuclease-free water were sent for sequencing (Functional Genomics, Biosciences, Birmingham). 
 
Western blotting and nuclear extract 
Proteins were harvested in 200µl RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% v/v Igepal CA-
630, 6 mM sodium deoxycholate, 1mM EDTA) containing protease inhibitor cocktail (Sigma, Dorset, UK). 
Protein concentration was measured using BCA assay using Bovine serum albumin (BSA) as protein 
standards.   
Samples were prepared for loading by combining with 4x Laemmli buffer at a ratio of 3:1 
protein: laemmli buffer and denatured for 5 minutes at 95°C.  Equal masses of proteins were loaded into 
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wells along with one well containing 5µl of protein ladder (Precision Plus protein standards dual colour- 
BioRad). Proteins were separated by electrophoresis at 70 V through 4.5% stacking gels and then 140 V 
through 12% resolving gels. Proteins were transferred to polyvinylidene fluoride membranes (PVDF), 
followed by blocking in 5% non-fat milk in Tris-Buffered Saline with Tween (TBST) overnight at 4°C or for 
1 hour at room temperature. Membranes were then incubated with primary antibodies in 5% non-fat 
milk in TBST overnight at 4°C or for 1 hour at room temperature. After washing in TBST (three washes of 
10 minutes) blots were incubated with appropriate horseradish peroxidise conjugated secondary 
antibodies for 1 hour at room temperature. After further washes (three washes of 10 minutes), protein 
bands were visualised by the ECL plus chemiluminescence detection system on Kodak film for 30 
seconds to 20 minutes. Primary antibodies for Western blotting include rabbit anti-PBF (1:500) (Smith et 
al., 2009), mouse anti-HA (1:1000) (Cambridge biosciences), mouse anti-lamin (1:250), mouse anti-
tubulin (1:250), rabbit anti-CRM1 (1:500) (Santa Cruz biotechnology) and mouse anti-β-actin (1:10,000). 
Secondary antibodies were rabbit anti-mouse (1:2000) and goat anti-rabbit (1:2000). 
For nuclear/cytoplasmics extracts, cells were seeded from T25s with a cell count of 
approximately 3.2 x 106 cells. Protein was extracted using a Nuclear Extract Kit (Active Motif) as per the 
manufacturer’s instructions. Protein concentration for each fraction was calculated using the BCA assay 
with BSA dissolved in the lysis buffer for the nuclear extract and hypotonic buffer for the cytoplasmic 
fraction. Western blotting of each fraction was then carried out as described above. 
 
Immunofluorescence 
24 hours after transfection, medium was removed from the coverslips and cells were briefly washed in 
phosphate-buffered saline (PBS).  Cells were incubated in 800µl fixing solution (0.1 M phosphate buffer 
(pH 7.4) containing 2% paraformaldehyde, 2% glucose and 0.2% sodium azide) for 20 minutes at room 
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temperature. After washing twice in PBS, the cells were permeabilised in ice-cold absolute methanol for 
10 minutes at -20°C. Cells were rinsed twice in PBS and blocked in 10% newborn calf serum (NCS) in PBS 
at room temperature for 30 minutes, followed by incubation with primary antibody at room 
temperature for 1 hour in 1% BSA in PBS. Primary antibodies used were rabbit anti-PBF (1:150), mouse 
anti-HA (1:200), rabbit anti-CRM1 (1:150) and mouse anti-fibrillarin (1:150) (Abcam). Following three 
rinses in PBS, cells were incubated for another hour in secondary antibodies in 1% BSA, 1% NCS in PBS. 
Secondary antibodies were as follows: Alexa-Fluor 488-conjugated goat anti-mouse IgG and Alexa-Fluor-
594-conjugated goat anti-rabbit IgG (Invitrogen) both used at 1:250 along with Hoechst 33342 stain for 
nuclei (1:1000). Coverslips were rinsed a further three times in PBS before being mounted onto slides 
with Dako Fluorescent Mounting Solution (Dako, Denmark). After at least 5 hours drying, cells were then 
visualised using 40x and 100x objective on Zeiss Axioplan fluorescent microscope (Zeiss, Germany).  
 
Disrupting CRM1 
siRNA was the first method used to disrupt the CRM1. siRNA transfection was carried out using 
Lipofectamine reagent (Invitrogen) at 6µl per 1ml of Opti-MEM media. For protein extraction and 
immunofluorescence (IF) staining, cells were seeded in six-well plates (containing sterile coverslips for 
IF) and transfected with 1µl of relevant siRNA (40nmol) after 24 hours. For nuclear/cytoplasmic extracts 
cells, were seeded in T25 flasks and transfected with 5µl of relevant siRNA (40nmol). siRNAs used were 
CRM1-specific siRNA (Ambion) and the negative control scrambled siRNA silencer (Ambion). The second 
method utilised the CRM-1 specific inhibitor, Leptomycin B solution (L2913, Sigma Aldrich). The stock 
Leptomycin B solution was at 2µg/ml dissolved in 70% methanol and was used at a range of 
concentrations from 1ng/ml – 5ng/ml. For every Leptomycin B experiment, a vehicle only control using 
the same volume of 70% methanol was carried out in parallel.  
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Results 
Location of HA-tagged PBF 
To establish whether HA-tagged PBF can localise to the nucleus two different approaches were taken. A 
nuclear extract kit was used to compartmentalise the proteins found in the nucleus from those in the 
cytoplasm, followed by Western blotting to identify which compartment the protein was located in. The 
second approach was immunofluorescence, which allowed direct visualisation of the protein’s location 
within cells. 
Initially the nuclear extract experiment was carried out on non-transfected cells to show that an 
efficient split between the different fractions was achievable in the cell-lines. Tubulin was used as a 
marker for the cytoplasm whereas lamin was used as the nuclear marker. The nuclear extract 
experiment was very variable and only worked with larger cells such as COS7 and HeLAs rather than the 
smaller TPC-1s and K1s (Figure 4A).  
After showing that COS7 cells could be successfully fractionated, cells were then transfected 
with PBF, PBF-HA and mutant 1 along with a pcDNA3 vector only control. Mutant 1 is also C-terminal 
HA-tagged and is missing the last 30 amino acid residues, including PBF’s NLS and sorting signal. The blot 
suggests that PBF is mainly a nuclear protein, with very little being found in the cytoplasmic fraction 
(Figure 4B). When probed with PBF antibody, PBF was present in the nucleus in all cases. However in the 
case of PBF-HA and mutant 1, it is likely the PBF shown is endogenous rather than transfected form. 
When probed with HA antibody, as predicted, the majority of the protein was located in the cytoplasmic 
fractions. However, there appeared to be a small amount present in the nuclear fraction, which may be 
due to the fact that the nuclear membrane can often be pulled down into the nuclear fraction and if 
PBF-HA was accumulating there, there is potential for a small amount of carry over. The Western blots 
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also revealed that PBF appears to form dimers in nucleus, whereas the predominant isoform in the 
cytoplasm was monomeric. PBF is a glycoprotein, and variously glycoslyated forms normally range 
between 28 and 37kDa.  
 
  
Figure 4 – Nuclear/Cytoplasmic Fractionation 
4A – Nuclear/Cytoplasmic Fractions –COS7 cells 
were fractionated using the Nuclear Extract Kit (see 
methods and materials). Antibodies to Lamin A/C and 
tubulin were used to show successful division, as 
lamin is exclusively a nuclear protein and tubulin is 
exclusively found in the cytoplasm. 
4B – PBF is primarily a nuclear protein, yet HA-
tagged PBF is not present in the nucleus – COS7 cells 
were transfected with pcDNA3 vector only, PBF, PBF-
HA and mutant 1 plasmids for 24 hours, before being  
harvested and separated into nuclear and 
cytoplasmic fractions using the Nuclear Extract Kit 
(see methods and materials). The top panel shows 
the membrane being probed with a PBF specific 
antibody whereas the bottom panel has been probed 
using a HA specific antibody. Probing with PBF 
antibody shows PBF to be mainly located in the 
nucleus.  When probed with HA antibody there is 
evidence that HA-tagged PBF is mainly a cytoplasmic 
protein with little to none being located in the 
nucleus. 
 
A 
B 
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Immunofluorescence in all four cell lines reinforced the hypothesis that HA-tagged PBF is unable to 
enter the nucleus, confirming the Western blot findings. As can be seen in Figure 5, when PBF-HA was 
transfected into the cell, there appeared to be a ‘halo’-like green ring around the nucleus, suggesting 
that nuclear entry is blocked for the protein. The slight green staining that appeared to be in the nucleus 
in some of the images is likely to be tagged PBF that is present in the cytoplasm above the nucleus, as 
the image is a 2D shot of a 3D structure. However confocal microscopy would be needed to verify this.  
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Figure 5 – HA-tagged PBF is not present in the nucleus – COS7 and TPC-1 cell-lines were seeded on 
coverslips and transfected with pcDNA3 vector only, PBF, PBF-HA or Mutant 1 for 24 hours. Antibodies 
specific to PBF (red) and HA (green) were used to probe the coverslips, followed by fluorescently 
tagged secondary antibodies to allow visualisation of the proteins using fluorescence microscopy. 
Hoechst stain (blue) was used to visualise nucleoli. The green staining suggests that HA-tagged PBF 
accumulates at the nuclear membrane and is not present in the nucleus; whereas WT PBF is both a 
cytoplasmic and nuclear protein. Images were taken at 100x magnification. 
COS7 
TPC-1 
23 
 
Deleting the HA tag from dual tagged PBF 
To enable transfected PBF to be discerned endogenous PBF, it needs to be labelled with a fluorescent 
tag. The HA tag has been shown to block nuclear entry of PBF, therefore interfering with PBF’s function, 
so a different tag would be preferential. The group have a FLAG tagged version of PBF in which the 
protein is also C-terminally HA tagged; the FLAG tag is inserted after residue 34 in PBF. To remove the 
HA tag, site-directed mutagenesis was attempted to delete the HA-tag sequence from the dual-tagged 
plasmid (Figure 6A). Unfortunately the mutagenesis was unsuccessful and the sequencing revealed that 
all the samples still contained the HA tag (Figure 6B). The process was repeated with an optimisation 
step of adding PCR enhancer to try and improve the efficiency of the reaction. Again unfortunately the 
reaction was unsuccessful and the HA tag remained intact. 
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Figure 6 – Deletion of the HA Tag from PBF 
A  - Mechanism of deleting the HA tag from PBF – Primers are designed to anneal to and extend only 
PBF and the pcDNA3 backbone, missing out the HA tag, so the HA tag is no longer coded for in newly 
synthesised DNA. 
B –Unsuccessful deletion of the HA tag from PBF – The sequencing shows that the HA tag was not 
deleted from the PBF plasmid. If the tag had successfully been deleted the sequence would have read 
ACAACTAATCT rather than the ACAACTACCAT as circled above. 
  
PBF
pcDNA3
FLAG
HA
Primer
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Mutating the NES 
To investigate whether the nuclear export signal (NES) is functional in PBF, the signal needs to be 
disrupted and compared to PBF with a normal NES. Mutagenesis can be used to introduce mutations 
into plasmid DNA. Mutation of the NES was attempted, with the aim that prediction software would no 
longer recognise the NES, but the N-terminal signal peptide sequence would not be affected. Various 
mutations were entered into prediction software to determine which one would be the most efficient at 
disrupting the NES signal, while leaving the signal peptide intact. Mutating Leucine 17 to an Alanine and 
Leucine 22 to Alanine provided a total depletion in NES prediction. Site-directed mutagenesis was then 
attempted using primers designed to induce the dual mutation (see Materials and Methods). However, 
the mutagenesis failed and no bacterial colonies grew. Attempts to solely mutate Leucine 17 to Alanine 
were then made using a new set of primers (see Materials and Methods), as this single mutation 
provided the smallest NES signal from the residues involved; however again these attempts led to failure 
to grow bacterial colonies. Mutagenesis was repeated, with both primer sets, using a two step protocol 
as described in Wang and Malcolm (1999) and with the PCR enhancer; again these unfortunately failed 
to grow colonies. Due to the repeated failure of the mutagenesis, it was decided to take a different 
approach to interrupt the NES function. 
 
Silencing CRM1 
As CRM1 is the main protein involved in nuclear export, particularly with proteins containing a 
hydrophobic nuclear export signal, like PBF, it was decided to knock this protein down and see if there 
was any difference in the localisation of PBF. CRM1 was knocked down using a CRM1-specific siRNA. To 
confirm efficient knockdown of the CRM1, Western blotting and immunofluorescence were used to 
compare protein levels between scrambled and CRM1 specific siRNAs (Figure 7A).  Once confirmed that 
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knockdown was efficient it was then used in the variety of cell-lines transfected with VO and PBF.  Using 
immunofluorescence, the effect of CRM1 knockdown on the location of PBF was examined in COS7 cells 
(Figure 7B). Knockdown of CRM1 in COS7 cells led to reduced staining for PBF in the cell cytoplasm and 
also appears to have blocked PBF’s entry to the nucleolus. In the control, with scrambled siRNA, there 
appeared to be colocalisation between PBF and fibrillarin (a nucleolus marker) depicted by the yellow 
staining. However when CRM1 levels were depleted there was no colocalisation and PBF appeared to 
form halo-like structures around the periphery of the fibrillarin. When PBF was solely examined it was 
evident that there were regions of the cell that PBF was being excluded from, observed by the holes in 
the staining. A similar effect was observed in K1 cells (Appendix 1).  CRM1 was further knocked-down in 
COS7 cells transfected with PBF-HA, to investigate whether HA-tagged can enter the nucleus or if was 
entering but then being exported (Figure 7C). There was no difference in the location PBF-HA between 
control or CRM1 knockdown, suggesting that PBF-HA cannot enter the nucleus to begin with and the 
lack of presence in nucleus is not due to nuclear export. 
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Figure 7 – Knockdown of CRM1  
7A – Efficient knockdown by siRNA – Western blotting and immunofluorescence showed efficient knockdown of 
CRM1 in COS7s. Cells were transfected with scrambled or CRM1 siRNA (40 nmol) for 24 hours before probing with 
CRM1 specific antibody (red in immunofluorescence). Microscopy images were taken at 100x magnification. 
7B – Knockdown of CRM1 decreases cytoplasmic PBF – COS7 cells were transfected with either scrambled 
(negative control) siRNA or CRM1 siRNA (40 nmol) for 24 hours. Coverslips were probed with PBF (red) and 
fibrillarin (green) antibodies while nucleoli were stained blue with Hoechst stain. When CRM1 was knocked down 
there appeared to be less cytoplasmic and nucleolar PBF compared to control. Images were taken at 100x 
magnification. 
7C – CRM1 is not responsible for PBF-HA not being present in the nucleus – COS7 cells transfected with PBF-HA 
were also transfected with scrambled or CRM1 siRNA (40 nmol) for 24 hours. Coverslips were probed with PBF 
(red) and HA (green) specific antibodies while nucleoli were stained blue with Hoechst stain. There was little 
difference between the locations of PBF-HA in either treatment suggesting accumulation of PBF-HA at the nuclear 
membrane is not due to nuclear export. Images were taken at 100x magnification. 
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Inhibition of CRM1 using Leptomycin B 
Along with CRM1 knockdown, to further study the effect of CRM1 on PBF, Leptomycin B (LMB) was used 
as a potent inhibitor of CRM1. To optimise the treatment, the inhibitor was used at a variety of different 
timepoints, at different concentrations, in different cell lines. As observed in K1s (Figure 8), even at the 
lowest concentration of inhibitor there were visible effects of LMB. Again there appeared to be less 
cytoplasmic PBF and more unstained regions that correspond with the nucleolus.  There were more 
apparent holes in the staining, but unlike the siRNA treatment there was no accumulation of PBF at the 
boundary of the nucleolus. At 8 hours with only 1ng/ml, the cells appeared to begin to recover with 
there being more cytoplasmic PBF present and more distributed staining in the nucleus; in fact there 
appeared to be an excess of PBF in the nucleolus. This effect was also observed in COS7 and HeLA cells 
treated in the same manner (Appendix 2 and 3). 
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Vechicle Only 
PBF DAPIFibrillarin
Leptomycin B  - 1ng/ml
2hr
5hr
8hr
Leptomycin B  - 2ng/ml
2hr
5hr
8hr
Leptomycin B  - 5ng/ml
2hr
5hr
8hr
Figure 8 – K1 cells treated with different concentrations of Leptomycin B for different lengths of time - K1s 
were seeded on coverslips and incubated with either vehicle only (DMSO) or varying concentrations (1,2 or 
5ngml) of the CRM1 inhibitor, Leptomycin B, for 2, 5 or 8 hours. Coverslips were probed with PBF (red) and 
fibrillarin (green) specific antibodies while nucleoli were stained blue with Hoechst stain. Images were taken 
at 100x magnification. 
ehicle Only 
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Homology 
A localisation signal is more likely to be functional if the signal is conserved within other species. The 
sequences of PBF in four different species and the predicted sequences of PBF in another three species 
were obtained from the National Center for Biotechnology Information (NCBI) Homologene tool 
(http://www.ncbi.nlm.nih.gov/homologene). The sequences were aligned to allow easy comparison 
using the NCBI Constraint-based Multiple Alignment Tool (COBALT). The peptide sequences were also 
entered into the CBS prediction server to see if they also contain a predicted nuclear export sequence. 
All of the species, except Gallus gallus, had sequences that contained an NES score that exceeded the 
threshold of 0.5 on the NES score (Figure 9). The positioning of the potentially involved amino acids, 
shows the high level of homology between PBF sequences among different species. However, although 
most the sequences contain amino acids predicted to participate in a nuclear export signal, most of the 
species contain only one or two residues expected to be involved, suggesting the signal is unlikely to be 
functional in most of the species.  
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Figure 9 – NES positions and scores for PBF in different species – The top panel shows the NES score of 
PBF in 7 different species including Homo sapiens. Where the red line (NES Score) crosses the pink 
threshold line, residues are predicted to be involved in NES. The bottom panel shows the positioning of 
the NES scoring residues in PBF of the same seven species. The NES consensus sequence is LxxxLxxLxL, 
where "L" is a hydrophobic residue (often leucine) and "x" is any other amino acid.  
Homo sapiens 
Pan troglodytes 
Canis lupus familiaris 
Bos Taurus 
Mus musculus 
Rattus norvegicus 
Gallus gallus 
Homo sapiens 
Pan troglodytes 
Canis lupus familiaris 
Bos Taurus 
Mus musculus 
Rattus norvegicus 
Gallus gallus 
TPYWRLRLGGAALLLLLIPVAA 
TPYWRLRLGGAALLLLLIPVAA 
GPRWELPRGAVALFLLLLSAAA 
TPRWGPTLGSAAFLLLLPAAAA 
TPHWVMLLG--AVLLLLLSGAS 
TLRWVMFLS--AVLLLLLPGAS 
DPAPPPDSSAAPSEGGAWPRAR 
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Discussion 
Location of HA-tagged PBF 
As was observed by immunofluorescence and cell fractionation, HA-tagged PBF is unable to translocate 
to the nucleus unlike endogenous WT PBF. This is likely to be due to the HA tag being added to the C-
terminus of PBF close to the NLS. Nuclear import is a regulated process that involves importins binding 
to cargo proteins, transporting them through the nuclear envelope as a complex and releasing them on 
the other side. The most commonly used pathway for a cargo protein with a bipartite NLS, such as PBF, 
is through the use of importin α as an adaptor protein. Importin α contains two binding sites for NLS in 
the form of Armadillo (ARM) tandem repeats; the repeats form a banana-shaped structure with the 
crucial NLS binding residues tryptophan, asparagine and acidic amino acids lining the inner concave of 
the molecule (Fontes, Teh and Kobe, 2000). The basic residues that form NLS are recognised by these 
molecules and make specific interactions with them. The primary binding site, ARM repeats 1-4 is 
occupied by the larger part of the bipartite NLS, with repeats 6-8 accommodating the second smaller 
part. The location of NLS are usually in unstructured extended regions of the protein, so the protein can 
adapt to bind the importin. Once bound to importin α, the complex further binds to importin β in the 
cytoplasm and then translocates to the nucleus through nuclear pore complexes (NPCs). Once in the 
nucleus, both importins dissociate and the cargo protein is released (Stewart, 2007). With the HA tag 
being within 15 residues from the end of the bipartite NLS, it is probable that when PBF is folded as it 
would be in the cell, the HA is looping round and concealing the residues involved in the NLS so importin 
α can no longer recognise or interact with them, meaning that PBF is denied entry into the nucleus. 
Blocking entry into the nucleus may be interfering with a significant amount of PBF’s role, as PBF has 
been shown to interact with an array of DNA damage proteins, such as p53, Rad6 and mdm2 (Read et 
al., 2012), so a N-terminally tagged version of PBF may be more appropriate, as it has already seen to be 
able to enter the nucleus in the previous study by Chien and Pei (2000). 
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Mutagenesis 
As described earlier, mutating the NES in PBF and studying the effect was a major aim of this 
investigation but led to repeated failures. Unfortunately this is probably due to limitations within PBF 
itself; the region coding for the NES is extremely GC rich (>70%). The mutagensis kit used recommends 
using primers with a GC content between 40-60%, however, such a low percentage in this region of PBF 
is unattainable.  Having such a high GC content leads to the primers forming complex secondary 
structures and mispriming, as guanine repeats form intra and interstrand folding by hydogen bonding 
with neigbouring guanines  (Jensen, Fukushima and Davis, 2010). As such a high GC primer content is 
inevitable with this mutation, unfortunately oligonucleotide-directed mutagenesis appears to be 
unsuitable and a new method needs to be sought. One such method is to delete a fragment of PBF using 
restriction enzymes and  reintoduce the fragment as an oligonucleotide containing the desired 
mutation. This method of restriction fragment deletion may also provide more successful results for 
removing the HA tag from PBF. 
 
Functional NES? 
The fact that there is very little homology in the NES between species suggests the signal is likely not be 
functional. However, data from experiments with CRM1 suggests there may be a role for the NES in 
Homo sapiens at least.  In many immunofluorescence images where CRM1 was inhibited or depleted, 
there appeared to be reduced levels of cytoplasmic PBF, suggesting less PBF is being exported from the 
nucleus. Nuclear/Cytoplasmic fractionation +/- LMB or CRM1 siRNA would be ideal methods to confirm 
this observation, but unfortunately due to constraints of the kit, the fractionation was unsuccessful on 
treated cells.  With the homology data showing that the NES has not been conserved through evolution 
and the images between different cell lines not being fully consistent, it is likely that CRM1 does have a 
role in the nuclear export of PBF, yet it may not be PBF’s only way out of the nucleus. 
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 One thing that is clearly evident though, is the increased number of unstained regions that 
correspond with the nucleolus, marked using fibrillarin, especially when CRM1 is knocked down. The 
nucleolus is a subnuclear organelle that is not bound by a membrane, and is fundamental for rRNA 
processing and ribosome production, but also has non-traditional roles such as protein degradation, cell 
cycle regulation and cell stress responses. The nucleolus has also been shown to be a major regulator of 
proliferation and cell growth by being able to modulate the compartmentalization of p53 and mdm2 
(Chennupati et al., 2011). CRM1 was first reported to transport molecules from the nucleoplasm to the 
nucleolus by Boulon, et al (2004), where they observed that CRM1 was responsible for transporting U3 
small nucleolar ribonucleoprotein (snoRNP) from cajal bodies to the nucleolus. In 2009, the transport of 
the cytoplasmic polyadenylation element-binding protein 1 (CPEB1) to the nucleolus was studied by 
Ernoult-Lange, et al; they reported that when CRM1 was inhibited by LMB, CPEB1 was excluded from 
the nucleolus producing immunofluorscence images similar to those observed with PBF. They went on 
to describe how CRM1 formed bodies in the nucleolus which they termed CNoBs (CRM1 Nucleolar 
Bodies). CPEB1 colocalised with these CNoBs when tranfected into HeLA cells, but when treated with 
LMB, the CNoBs vanished both in tranfected and untransfected cells (Ernoult-Lange et al., 2009). If PBF 
is interacting with CRM1 in the cell as suspected, perhaps it is also found in these CNoBS, and when 
CRM1 is inhibited with LMB, there appeared to be unstained PBF regions in the nucleolus as the CNoBs 
no longer exist.  
 If PBF is truly found in CNoBS, it potentially opens up a wider variety of roles for the largely 
uncharacterised protein. Both p53 and mdm2 have been shown to interact with CRM1 in the role of 
nuclear export,  and have roles in the nucleolus, so perhaps these CNoBs act as a platform for their 
interactions with PBF. The CNoBs have also been hypothesised to be involved in ribosomal transcription 
(Ernoult-Lange et al., 2009). If proven, PBF could prospectively have a role in the process. Unfortunately 
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all these roles are purely speculative and a considerable amount of further investigation would be 
needed to confirm these hypothesises. 
 
Further Work 
With regards to the nuclear export of PBF, there are two main experiments that would be required to 
establish whether the NES is functional and if CRM1 is responsible for nuclear export.  The prime task is 
to create a PBF plasmid containing the NES mutation. This would hopefully be possible through gene 
cloning as described above. Once a mutant is generated, immunofluorscence could be used to establish 
any differences in the location of WT PBF and ΔNES PBF; the location of the mutant could also be verfied 
by nuclear/cytoplasmic fractioning. To confirm whether CRM1 is involved in the nuclear export of PBF, 
optimisation of the nuclear/cytoplasmic fractionation protocol with LMB treated and CRM1 knocked 
down cells would be advantangeous to quantify differences in the levels of PBF between fractions using 
densitometry. 
Another key task for furthering this work would be the development of a tagged form of PBF 
that is capable of nuclear entry. This PBF could be created in one of two ways,  either by deleting the 
HA-tag from the dual tagged PBF by restriction fragment deletion, depending on locations of restriction 
sites, or by N-terminally inserting a HA-/FLAG-tag instead. After establishing that this newly tagged form 
of PBF is capable of nuclear entry, interactions between CRM1 and PBF could be truly determined. Co-
immunopreciptiation and confocal microscopy would be essential techniques for studying the proteins 
interactions and confirming PBF is colocalising in CNoBs. If this is observed, as hypothesised, further 
work could then focus on whether CNoBs are acting as a platform for PBF’s interactions with other 
proteins or for undetermined roles of PBF. 
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Appendices 
 
 
 
Appendix 1 - Knockdown of CRM1 decreases cytoplasmic PBF –K1 cells were transfected with either 
vector only pcDNA3 or PBF plasmids for 24 hours. The differently transfected cells were then further 
transfected with either scrambled (negative control) siRNA or CRM1 siRNA (40 nmol) for 24 hours. 
Coverslips were probed with PBF (red) and fibrillarin (green) antibodies while nucleoli were stained blue 
with Hoechst stain. The top two rows of images show the effect of CRM1 siRNA on endogenous PBF, 
whereas the lower two on cells with transfected PBF. When CRM1 was knocked down, there appeared 
to be less cytoplasmic and nucleolar PBF compared to control, in both endogenous and overexpressed 
situations. Images were taken at 100x magnification.  
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Appendix 2 – COS7 cells treated with different concentrations of Leptomycin B for different lengths of 
time – COS7s were seeded on coverslips and incubated with either vehicle only or the CRM1 inhibitor, 
Leptomycin B, at either 1, 2 or 5 ng/ml for 2, 5 or 8 hours. Coverslips were probed with PBF (red) and 
fibrillarin (green) specific antibodies while nucleoli were stained blue with Hoechst stain. Images were 
taken at 100x magnification. 
 
 
Vehicle Only Leptomycin B  - 1ng/ml
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Leptomycin B  - 2ng/ml
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Leptomycin B  - 5ng/ml
2hr
PBF Fibrillarin DAPI
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Appendix 3 – HeLA cells treated with different concentrations of Leptomycin B for different lengths of 
time – HeLAs were seeded on coverslips and incubated with either vehicle only or the CRM1 inhibitor, 
Leptomycin B, at either 1, 2 or 5 ng/ml for 2, 5 or 8 hours. Coverslips were probed with PBF (red) and 
fibrillarin (green) specific antibodies while nucleoli were stained blue with Hoechst stain. Images were 
taken at 100x magnification. 
  
Vehicle Only Leptomycin B  - 1ng/ml
2hr
8hr
Leptomycin B  - 2ng/ml
2hr
5hr
8hr
Leptomycin B  - 5ng/ml
2hr
PBF Fibrillarin DAPI
5hr
8hr
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Abstract 
Colorectal cancer (CRC) is a leading cause of cancer death, causing 16,000 deaths each year in the UK 
alone. Obesity is a major risk factor for CRC, and with a quarter of the UK being classified as clinically 
obese, it is important to establish how obesity affects CRC. Recently, adipose tissue has been described 
as an endocrine organ, secreting hormones that may be mediators of CRC proliferation. In this study, 
human adipocytes were cultured and their secretomes collected prior to and after adiopogenesis. The 
adipocyte conditioned media was analysed to identify the components and their effect on CRC cells. The 
study showed that differentiated ACM was capable of increasing both the viability and proliferation of 
CRC cells. Antibody arrays and ELISA detected the presence of the adipokines, leptin, IL-6 and hepcidin, 
in differentiated ACM. All three adipokines were individually observed to increase proliferation and 
viability of CRC cells. Mechanistic analysis, using hepcidin inhibition and reporter assays, suggest that 
there is a trend towards leptin and IL-6 functioning by increasing hepcidin expression in CRC cells. There 
is also emerging evidence to suggest that IL-6 and leptin are capable of functioning through the Wnt 
signalling pathway. 
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Introduction 
Colorectal Cancer 
The mammalian colon is compromised of four major sections (the ascending, the transverse, the 
descending and the sigmoid colon) and with the rectum makes up the large bowel (Figure 10). The main 
function of the colon is to store faecal matter and regulate its release while absorbing electrolytes and 
water (CRUK, 2011).  
 
Figure 10 - Anatomy of the Colon - Taken from Colonic Clinic, 2011 
Carcinoma of the colon or rectum is referred to as colorectal cancer (CRC) or bowel cancer, and is the 
third most common cancer in the UK, being responsible for around 16,000 deaths a year in the UK alone 
(Statistics, 2010). CRC usually originates in the epithelial cells lining the colon, starting out as a benign 
polyp before becoming malignant. Treatment varies depending on how advanced the cancer is, but the 
principal aim is total resection of the tumour; surgery can be curative in cases caught early, but adjuvant 
chemotherapy and radiation may be given if the cancer is more advanced. If the disease has become 
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metastatic, however, palliative care is often the only option (Cunningham et al., 2010). The major 
contributing factors for CRC are diet, lifestyle and increasing age, with minority factors including family 
history of CRC, hereditary conditions, such as familial adenomatour polyposis (FAP) and hereditary non 
polyposis colorectal cancer (HNPCC), and chronic bowel diseases, such as ulcerative colitis and Crohn’s 
disease (CRUK, 2011). Diet is a major contributor to CRC, particularly in the western world where diets 
consist of high-fat iron-loaded meats and very little fibre; along with diet, obesity has been shown to 
significantly correlate with colon cancer risk in both men and women (Larsson and Wolk, 2007). 
 
Obesity 
Obesity is defined by the World Health Organisation (WHO) as abnormal or excessive fat accumulation 
that may impair health, giving the definition a body mass index (BMI) value of above 30 (WHO, 2012). In 
2009, almost a quarter of adults in England were classified as clinically obese with this percentage 
steadily rising (The NHS Information Centre, 2011). A study in 2001 identified that the cancers most 
associated with obesity include breast, endometrium, colon and kidney (Bergstorn et al., 2001). 
Together with its association with cancer, obesity is also a leading cause of other conditions including 
diabetes, hypertension, infertility, ischemic heart disease and stroke. 
Adipose tissue, or fat, is not only vital for cushioning major organs but it is essential for the 
storage of lipids, however, having too much is problematic. There are two major depots of fat, visceral 
or subcutaneous, which are classified by their locations in the body and each produces a unique 
spectrum of adipokines (Samaras et al., 2010). The greater omentum is a large visceral fat pad, mainly 
comprised of adipocytes, that functions as the ‘policeman’ of the abdomen and is a storage site for 
energy-dense lipids. Adipose tissue is increasingly being described as an endocrine organ, due to its 
ability to produce adipokines; these adipokines are being found to have new roles outside the 
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traditional energy homeostasis and are being implicated as mediators of obesity’s link with cancer. 
Adipokines are cytokines secreted by adipose tissue; over 200 have been identified, with at least 50 
being exclusive to adipocytes (Paz-Filho et al., 2011). Adipose tissue is comprised of mainly mature 
differentiated adipocytes, with a small percentage of immature preadipocytes; these preadipocytes 
undergo adipogenesis, a series of morphological changes along with cessation of cell growth, expression 
of many lipogenic enzymes and extensive lipid accumulation to become fully differentiated (Rosen and 
Spiegelman, 2000). Differentiation also leads to changes in their secretomes (Rosenow et al., 2010). This 
study primarily concentrates on the adipokines leptin, inter-leukin 6 (IL-6) and hepcidin. 
 
Leptin 
Leptin is a 16kDa hormone that is comprised of 167 amino acids and is predominantly, but not 
exclusively, produced by adipocytes (Hardwick et al., 2001). Circulating leptin levels have been shown to 
positively correlate with adipose tissue mass, linking obesity with increased leptin concentrations (Paz-
Filho et al., 2011). Leptin was first characterised in mice as a product of the obese (ob) gene, a 
homologue of the human LEP gene (Gunter and Leitzmann, 2006). When energy levels are high, in 
healthy individuals, leptin is produced to reduce appetite; however in an obese state, adipose tissue 
overproduces leptin leading to the body becoming desensitised to the signal and appetite is no longer 
reduced (Harvey, Lashinger and Hursting, 2011). Along with being involved in controlling appetite, leptin 
has also been shown to be a growth factor for many cell types, including colon epithelial cells (Hardwick 
et al., 2001). Leptin is detected at the cell surface by the leptin receptor, a single membrane spanning 
protein, which is ubiquitously expressed in most tissues (Sun et al., 2010); RNA splicing causes the 
expression of several isoforms of the receptor. Different isoforms of the receptor have been shown to 
interact with different signalling pathways, for example, the full-length isoform signals through the 
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Janus Kinase (JAK)/ signal transducer and activator of transcription (STAT) pathway, whereas the short 
isoform is involved in the mitogen-activated protein kinase (MAPK) signal transduction pathway 
(Hardwick et al., 2001). 
 
IL-6 
Inter-leukin 6 (IL-6) is a pleiotropic cytokine heavily involved in inflammatory responses; it was first 
identified as a B cell differentiation factor (Akira et al., 1990). Serum IL-6 levels have been shown to be 
significantly increased in obesity (Roytblat et al., 2000), suggesting that obesity is a chronic pro-
inflammatory state (Fenton and Birmingham, 2010). A variety of different cell types are capable of 
excreting IL-6 in both homeostatic and inflammatory circumstances, including adipocytes (Vicennati et 
al., 2002). IL-6 functions through two different receptors, primarily glycoprotein 130 (gp130), the less 
specific receptor that is also able to interact with molecules such as leukaemia inhibitory factor (LIF) and 
IL-11, and IL-6 receptor α (IL-6R α)(Meager and Wadhwa, 2007). IL-6 has also been associated with colon 
cancer, with both protein and mRNA levels being elevated in both serum and tumour samples 
(Bromberg and Wang, 2009).  
 
Hepcidin 
Hepcidin is a 22 amino acid long peptide that is known for being the ‘master regulator’ of iron. When it 
was first discovered in 2001, it was identified as being secreted by the liver to act as a urinary 
antimicrobial peptide (Lago et al., 2007), but subsequently since then other roles for the peptide have 
been established. The most studied role of hepcidin is its role in systemic iron haemostasis, where it has 
been shown to inhibit both the absorption of iron by enterocytes and the efflux of recycled iron from 
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macrophages. Hepcidin has also been shown to be upregulated in chronic inflammation (Peyssonnaux et 
al., 2007) and to be an adipokine, therefore increased levels have been shown to correlate with obesity 
(Bekri et al., 2006). In hepatocytes, hepcidin has been observed to be upregulated by both leptin (Chung 
et al., 2007) and IL-6 (Wrighting and Andrews, 2006). 
 
Adipokine targets 
Although adipokines have been identified, it has not yet fully established how they have their localised 
effects. Leptin and IL-6 have been shown to be mediators of the JAK/STAT signalling pathway and to 
induce hepcidin, but this may not be their only method of action. Several potential targets of the 
adipokines will be looked at in this study, these include: 
- Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) – also known as GRPR49, is a 
downstream target of Wnt signalling. Lgr5 has no known ligand nor mode of intracellular 
signalling, so is often referred to as an ‘orphan’ receptor (McClanahan et al., 2006). Increased 
expression in Lgr5 is due to Wnt signalling and in many colorectal cancers, where APC 
(adenomatous polyposis coli) is mutated, Lgr5 is overexpressed (Walker et al., 2011). 
- c-myc – cellular myc is a transcription factor that regulates cell proliferation. In many forms of 
cancer (e.g. lung and breast carcinoma), c-myc is found to be upregulated. Upregulation of c-
myc leads to multiple genes no longer being regulated, resulting in uncontrolled progression 
through the cell cycle and increased proliferation. c-myc is also a target gene of Wnt signalling 
(He et al., 1998), yet can be also regulated by MAPK and PI3K/Akt (phosphoinositide 3-
kinase/protein kinase B) (Zhu, Blenis and Yuan, 2008) pathways. c-myc has also been shown to 
regulate hepcidin levels (Bayele, McArdle and Srai, 2006) and have a role in apoptosis 
(Prendergast, 1999). 
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- Cyclin D1 – cyclin D1 is a key regulator in the cell cycle, promoting the transition from G1 to S 
phase; it has also been shown to have roles in cell metabolism and migration along with 
adipocyte differentiation (Fu et al., 2004) and to be induced by a variety of pathways including 
the MAPK, Wnt and JAK/STAT (Klein and Assoian, 2008). 
 
Wnt Signalling 
The Wnt signalling pathway induces the expression of target genes, such as β-catenin, Lgr5 and c-Myc, 
by allowing β-catenin to translocate to the nucleus and interact with T cell factor/lymphoid enhancer 
factor (TCF), activating it’s transcriptional properties (Figure 11); when there is no Wnt ligand present, 
the pathway is switched off as APC complexes with β-catenin, leading to its phosphorylation and 
degradation (Schneikert and Behrens, 2007). The Wnt family of proteins are key mediators in cell 
signalling, particularly in situations such as embryogenesis, but also in homeostasis and tissue 
maintenance, with perturbations leading to the development of cancer and degenerative diseases 
(Logan and Nusse, 2004). Wnt signalling is often deregulated in CRC, as mutations arise in APC or, less 
often, in β-catenin. Around 60% of mutations in APC, observed in CRC, are due to a point mutation, 
leading to the production of a stop codon which truncates the protein; this truncation means APC can 
no longer regulate β-catenin degradation (Schneikert and Behrens, 2007). The RKO cell-line used in this 
study is derived from a CRC that contains wild-type APC, whereas SW480 cells are APC null, so have 
constitutive Wnt signalling.  
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Figure 11 - Wnt Signalling - Taken from Logan and Nusse, 2004 – When there is no wnt ligand for the 
Frizzled receptor, as shown on the left, there is no signalling and therefore no transcription of target 
genes such as Lgr5. This is due to the fact β-catenin is inhibited by being phosphorylated and held in 
complex with a range of molecules including APC; this complex is then targeted for degradation. 
However when Wnt signalling is activated by a Wnt ligand binding to Frizzled, β-catenin is no longer held 
in complex, or degraded, and is free to act as a transcription factor for target genes. 
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Hypothesis 
Colorectal adenocarcinoma progression is accelerated by the cocktail of adipokines secreted from 
adipocytes. The adipokines involved are leptin and IL-6, which induce hepcidin production, stimulating 
the Wnt signalling. Hepcidin is also hypothesised to be an adipokine itself, being locally secreted by 
greater omental adipose tissue.  
 
Aims 
- To establish whether greater omentum adipose tissue secretes adipokines that accelerate 
colorectal cancer cell growth and proliferation. 
- To establish which adipokines are responsible for this phenotype. 
- To assess whether the adipokines are functioning through the Wnt signalling pathway. 
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Materials and Methods 
Cell Culture 
RKO and SW480 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) 
supplemented with 10% (v/v) heat-inactivated foetal calf serum (FCS) and 1% penicillin (105 
U/l)/streptomycin (100 mg/l) (P/S). All cultures were incubated at 37⁰C and 5% CO2 in humidified 
conditions and being passaged biweekly. 
 
Adipocyte Culture 
Samples were obtained from the BioBank, who had collected the samples from the greater omentum of 
consenting patients undergoing colorectal surgery. Following the removal of blood vessels and 
connective tissue samples were homogenised and incubated at 37⁰C for 1hour in 2mg/ml Collagenase II 
(C-6885 sigma) in DMEM F-12 (~5g sample per 10ml collagenase solution). After digestion, 10ml of 
serum-free DMEM F-12 media was added before the sample was filtered through sterile muslin gauze 
and spun for 5 minutes at 1500rpm. Supernatant was discarded and the pellet resuspended in serum-
free media, prior to being filtered through a falcon sieve and being centrifuged for 5 minutes at 
1500rpm. The supernatant was discarded and the pre-adipocyte pellet was resuspended in growth 
media (DMEM F-12 with 10% FCS and 1% P/S). The pre-adipocytes were plated onto 12-well Corning cell 
bind plates (Appleton woods) with ~6g of fat per plate. The cultures were incubated at 37°C and 5% CO2 
in humidified conditions. 
After overnight incubation, the cells were washed with serum-free media until there was no 
longer visible evidence of red blood cells. Cells were incubated in fresh growth media until deemed 
about 70% confluent; once confluent, growth media was removed and 1ml serum-free DMEM F-12 
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added overnight. The serum-free media was collected the following day and frozen for pre-
differentiated adipocyte secretome analysis. Cells were then given 1ml differentiation media (DMEM-
F12 with L glutamine (PAA) containing 1% P/S, 10% FCS, 33uM Biotin (B4639, Sigma), 17μM 
pantothenate (17018, Sigma) and 0.2nM T3 (T2877, Sigma)) which had 167nm insulin (19278, Sigma), 
1μM cortisol and 0.5μM 1-methyl-isobutylxanthine (IBMX) (17018, Sigma) added prior to use. After 4 
days, the media was removed and fresh differentiation media was added, but this time without IBMX; 
cells were cultured in this media until the adipocytes had fully differentiated (~14 days). Once 
differentiated, cells were placed in serum free DMEM F-12 media overnight and the media collected so 
the secretome from differentiated adipocytes could be analysed. A cycle of differentiation media and 
serum-free media was then carried out until the cells were no longer viable. After sufficient secretome 
was collected, samples were pooled according to their stage, pre-differentiated and differentiated 
adipocyte conditioned media (ACM). These pools were subsequently used in all further ACM 
experiments. 
 
Ethical Considerations 
Ethical approval was given by the Human Biology Research Centre, under the HBRC application code 11-
068. All patients consented to the resection of adipose tissue prior to surgery. 
 
Cell Stimulation and Inhibition Treatments 
ACM Media – Used on cells in viability and proliferation assays and RNA extraction, cells were 
stimulated with ACM, collected and pooled as described above. For ACM stimulation, differentiated 
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ACM was compared to pre-differentiated ACM (collected from immature cells) but also to serum-free 
DMEM F-12 media.  
No Stimulation – referred to as no ‘stim’ throughout, this control was of stim media (0.5% FCS, 1% P/S in 
DMEM) alone. As with all treatments, different volumes were used for different experiments as 
described per method. 
Leptin Stimulation – Leptin (stock 1mg/ml, Peprotech) was diluted in stim media to give a final 
concentration of 60ng/ml.  
IL-6 Stimulation – IL-6 (stock 100µg/ml, Peprotech) was diluted in stim media to give a final 
concentration of 10ng/ml. 
Hepcidin Stimulation – Hepcidin (stock 100µM, Alta Biosciences) was diluted in stim media to give a final 
concentration of 1µM. 
Leptin Inhibition – Anti-human leptin/OB Antibody (stock 500µg/ml, MAB398 R&D Systems) was diluted 
in stim media to give a final concentration of 3.2ng/ml. 
IL-6 Inhibition – Anti-human IL-6 antibody (stock 50µg/ml, 500-P26G Peprotech) was diluted in stim 
media to give a final concentration of 0.1ng/ml. 
Hepcidin Inhibition – Hepcidin antagonist peptide (Alta Biosciences) was dissolved in water to create a 
100µM stock solution, this was then diluted in stim media to give a final concentration of 1µM. 
 
Viability and Proliferation Assays 
Viability was assessed by using a MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) 
assay. MTT is a pale yellow tetrazole, which can be cleaved by mitochondrial dehydrogenase in cells that 
are viable and metabolically active. The cleavage products are dark blue formazan crystals that can be 
solubilised upon cell lysis; once lysed the colour and therefore absorbance are proportional to the 
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number of viable cells in each condition. RKO and SW480 cells were seeded at 7,500 per well in a 96 well 
plated and allowed to grow until 80% confluent. Media was then removed and samples were incubated 
with the appropriate stimulation/blocker (100μl per well for chemical stims, 50μl for ACM stimulation). 
After 24 hours with the appropriate stimulation, 10μl of MTT (5mg/ml in PBS) was added to each well 
and incubated at 37°C for 3 hours. Media was removed and 100μl of Dimethyl sulfoxide (DMSO) was 
added to each well to solubilise the crystals, before briefly shaking and reading the absorbance at 450Å 
using the Wallac Victor plate reader.  
 Proliferation was assessed using a cell proliferation ELISA BrdU (5-bromo-2'-deoxyuridine) 
(colorimetric) assay (Roche). BrdU is a synthetic pyrimidine analogue, which is incorporated in place of 
thymidine into DNA during replication. This analogue can be detected by a peroxidise conjugated BrdU 
antibody, which cleaves tetramethyl-benzidien (TMB) substrate producing a blue colouring, therefore 
providing a method to quantify proliferation. Cells were seeded and treated with different stimulations 
as in the viability assay above. After incubating for 24 hours, 10μl of 10μM BrdU labelling solution was 
added to each well before returning the plates to the incubator for 4 hours. Labelling solution was 
removed; 200μl FixDenat was added to each well for 30 minutes at room temperature before being 
removed. Once removed, 50μl of anti-BrdU-POD (10µM) was added to each well and left for 90 minutes. 
Antibody solution was then removed and the wells washed 3 times with 200μl BrdU wash solution 
before 100μl of BrdU substrate solution was added to each well. After brief shaking, the absorbance was 
then read 405Å using the Wallac Victor plate reader. 
 
Antibody-Array 
Pre-differentiated and differentiated secretomes were compared using the Human Adipokine Antibody 
Array 1 (RayBiotech), which was carried out as per manufacturer’s instructions. The film was then 
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scanned to create an electronic version using Biorad GS-800 Densiometry scanner and analysed using 
QuantityOne 4.6.7 (basic). 
 
Cellular Secretome Preparation 
RKO and SW480s were seeded into three Corning T75 vented flasks (per treatment) and cells were 
grown to 70% confluence in DMEM containing 10% FCS and 1% P/S. Once confluent, cells were then 
stimulated with no stim, leptin, hepcidin or IL-6. After 18 hours with the appropriate stimulation, cells 
were washed 4 times in sterile PBS, before 8ml of completely serum-free DMEM was added; 18 hours 
later the media was collected, sterile filtered and pooled per treatment and cell-line. Secretomes were 
stored at -20°C until required. 
 
Leptin, Hepcidin and IL-6 ELISAs 
Secretomes from RKOs and SW480s treated with no stim, Leptin, Hepcidin and IL-6 along with pre-
differentiated and differentiated ACM were assessed for Leptin, Hepcidin and IL-6 using ELISA (Enzyme-
linked immunosorbent assay). Human IL-6 Quantikine ELISA and human leptin Quantikine ELISA (R&D 
systems) were carried out as per manufacturer’s instructions. For the Hepcidin ELISA, secretomes were 
extracted using the S-500 extraction kit (Peninsula Laboratories) and then hepcidin levels were 
quantified using Hepcidin-25 (human) peptide enzyme immunoassay (Peninsula Laboratories) using 
protocol VI.  
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TOPFLASH reporter assay 
The TOPFLASH reporter is a dual-luciferase assay (Promega) that detects Wnt/β-catenin signalling 
activity. Cells were seeded 40,000 cells per well in 12 well plates and maintained until 60% confluent. 
Transfection master mixes were made up from the appropriate number of wells, that contained 0.8μg 
FOP or TOP plasmid (a kind gift from Bertovalstien et al), 0.1μg renilla (Promega), 3µl of Extremegene 
(Roche) and made up to 50µl with Optim-MEM media (Gibco, Invitrogen) per well. Media was removed 
from cells and replaced with fresh 10% FCS DMEM, before half the cells had 50µl of FOP transfection 
mix added to them and the other half had 50µl TOP mix. The cells were then incubated at 37°C for 18-24 
hours. Media was removed and 1ml of the appropriate stimulation media (either no stim, Leptin or IL-6) 
was added for 24hours. Media was then removed and the cells washed 3 times in non-sterile PBS, 200µl 
of passive lysis buffer (Promega), was added to each well and left on a rocker for 30 minutes, plates 
were then frozen at -20°C for at least 24 hours. Samples were thawed and 20µl of each sample was 
transferred to a white 96 well plate. At the plate reader, 50µl of Luciferase Assay Reagent II (LARII) was 
added to each well and immediately luminescence was measured on the Wallac Victor plate reader. The 
reaction was then stopped by the addition of 50µl of Stop and Glo reagent to each well and again 
luminescence was measured. 
 
Hepcidin reporter assay 
The hepcidin reporter is very similar to the TOPFLASH assay but instead identifies expression of hepcidin 
rather than Wnt targets. Cells are seeded in the same manner but are transfected with different 
plasmids. The transfection mixes for this are assay are compromised of 0.8μg Hepcidin (a kind gift from 
Dr Paul Sharp, Kings College London) or pGL3-basic plasmid (Promega), 0.1μg renilla (Promega), 3µl of 
TransIT-LT1 (Geneflow) and made up to 50µl with Optim-MEM media (Gibco, Invitrogen) per well. Cells 
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were transfected with these mixes, stimulated and measured in exactly the same way as the TOPFLASH 
assay above.  
 
RNA extraction 
Cells were seeded in 6 well plates at 75,000 per well. After 24 hours, cells were stimulated with either 
500µl ACM or 1ml of chemical stimulation. After incubation with the treatment for 24 hours, 200µl 
TRIzol reagent (Invitrogen) was added to each well and extracted using the TRIzol manufacturer’s 
protocol. After extraction, RNA was then quantified using a Nanodrop ND-1000 Spectrophotometer. 
 
cDNA generation 
Reverse transcription system (Eurogentec) was used to synthesise cDNA. Nuclease-free water and 0.4µg 
of RNA was combined to give a total volume of 8.1µl, which was then combined with 11.9µl of reverse 
transcription mastermix (4μl 25mM MgCl2, 2μl of reverse transcription buffer (10x), 4μl 2.5mM dNTP 
mix, 1µl random nonamer, 0.4µl RNAse inhibitor, 0.5µl EuroScript reverse transcriptase). The samples 
were subjected to a reverse transcription thermal cycle (BioRad My Cycler™ thermal cycler) as follows:- 
initial step - 10 minutes at 25°C; reverse transcriptase step - 30 minutes at 48°C; inactivation of reverse 
transcriptase enzyme - 5 minutes at 95°C; finally held at 4°C.  
 
TaqMan quantitative real-time polymerase chain reaction (qRT-PCR) 
1µl of cDNA was loaded in either duplicate or triplicate into a 96-well reaction plate, 14µl of the relevant 
qRT-PCR mastermix (Table 1 for myc, Table 2 for Lgr5, cyclin D1 and hepcidin) was then added. 18S 
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ribosomal RNA as used as an internal control throughout. The plate was then sealed and frozen at -20°C 
until needed. Once thawed the plates were pulse centrifuged and loaded into the Applied Biosystems 
7500 Fast Real-Time PCR detection system. The standard reaction protocol consisted of 10 minutes at 
95°C, 40 cycles of 10 seconds at 95°C and finally 1 minute at 60°C. After amplification, samples were the 
analysed using SDS software which allowed deduction of cycle threshold (CT) values. 
 
Reagent Volume per 
well (µl) 
Rox passive reference 4.8 
Sensimix  1200 
Myc Forward Primers 240 
Myc Reverse Primers 240 
Myc Probe 240 
18S Probe 12 
18S Primers 24 
Nuclease-free Water 29.2 
Table 1 - qRT-PCR master mix for Myc 
 
Reagent Volume per 
well (µl) 
Rox passive reference 4.8 
Sensimix  1200 
Relevant Taqman mix 
(containing primers and 
probe) 
160 
18S Probe 12 
18S Primers 24 
Nuclease-free Water 839.2 
Table 2 - qRT-PCR master mixes for Cyclin D1, Lgr5 and Hepcidin 
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Statistics 
Results are expressed as mean±SEM. Minitab was used to ensure the data was normally distributed 
before paired, two-tailed student T-tests were performed on Microsoft Excel. A P value of less than 0.05 
was regarded as significant. 
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Results 
Differentiation of Adipose Cells 
Pre-adipocytes were extracted from patient samples and cultured. Two different forms of adipocytes 
were cultured; the first being the immature pre-differentiated type, and the second the more mature 
differentiated type. The differentiated form, were the most interesting for this study, as they represent 
the majority of cells found in adipose tissue and are the cells that, in situ, would secrete the majority of 
adipokines. The pre-differentiated form can be used as an internal control, as they later mature into the 
differentiated type. To determine whether the cells were fully differentiated, microscopy was used, as 
there were obvious visible differences between the two cell types. Figure 12 shows the large differences 
between the two cell types; pre-differentiated adipocytes looked like normal cells, compared to the 
differentiated cells that were observed to contain large bubbles or vesicles storing triglycerides. 
Conditioned media was collected from both types of cells to analyse secretomes.  
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Figure 12 – Adipocytes in culture – Pre-adipocytes were extracted from patient samples and cultured in 
plates. (A) (magnification x5) shows the immature pre-differentiated adipocytes cultured in growth 
media (see methods and materials). (B) and (C) (magnification x5 and x40 respectively) show the more 
mature differentiated adipocytes, cultured in differentiation media (see methods and materials); these 
differentiated cells can clearly be distinguished due to being mainly comprised of large vesicles filled 
with triglycerides. 
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ACM’s effect on viability and proliferation 
The effect of conditioned media, from pre-differentiated and differentiated adipocytes on the viability 
and proliferation of two colorectal carcinoma cell-lines, was assessed. RKO and SW480 cell-lines were 
the primary cells used throughout this investigation as they are robust, easy to maintain and popular 
lines among colorectal carcinoma literature. Incubation with differentiated ACM led to significant 
increases in both proliferation and viability of both cell lines (Figure 13). Incubation with pre-
differentiated ACM led to a more varied response by increasing viability but decreasing proliferation.  
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Figure 13 – The effect of ACM on the viability (MTT assay) and proliferation (BrdU assay) of Colorectal 
Cancer cell-lines – SW480 and RKO cells were incubated with pre-differentiated and differentiated ACM 
along with serum free media overnight before MTT and BrdU assays were performed as described in 
materials and methods. Assays were quantified by changes in absorbance (at 450nm and 405nm for 
MTT and BrdU respectively).  Mean data ±SEM is plotted with * representing statistical significance 
(p<0.05), determined by a paired, two-tailed student T-test, compared to the relevant serum-free media 
control as.  n=3 with triplicate results in each n.  
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Determination of ACM constituents 
To determine what exactly is in the adipocyte secretome, a human adipokine antibody array was 
performed to see which of 64 potential molecules were found in the ACM from pre-differentiated and 
differentiated adipocytes. Of the 64 molecules tested for, there were 23 adipokines that increased by 
more than a factor of 0.5 from pre-differentiated ACM to differentiated ACM; yet there were only two 
(insulin and TIMP-2) that decreased by more than a factor of 0.25 (Figure 14A). The largest difference 
between the two ACMs was the volume of IL-6, with there being over a 50 fold increase in the levels of 
IL-6 in differentiated ACM compared to pre-differentiated (Figure 14B). Appendix 4 and Appendix 5 
show the differences between all 64 adipokines present on the array. 
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Figure 14 – Human adipokine Array Data – A human adipokine array containing antibodies to 64 
adipokines was used to probe pre-differentiated and differentiated ACM to establish which adipokines 
were present in each ACM. The density of the spots produced from the array was calculated using a 
densitometer, and the densities for both ACM normalised to pre-differentiated, for each adipokine, to 
allow comparison between the two ACM.  (A) shows the differences in the 24 adipokines (minus IL-6) 
that either increased by a factor of more than 0.5 or decreased by a factor of 0.25 between pre-
differentiated and differentiated ACM. (B) shows the massive increase in levels of IL-6 between pre-
differentiated ACM and differentiated ACM compared to the next largest increase, in the adipokine, 
ENA78. 
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To confirm the large increase in IL-6, a more specific IL-6 ELISA was used. The ELISA also allowed 
quantification of levels of IL-6 by the use of pre-determined standards. The use of the ELISA confirmed 
there was a large increase between IL-6 in differentiated ACM (217pg/ml) compared to pre-
differentiated ACM (7pg/ml), but quantified the increase to be a fold change of 29 (Figure 15) rather 
than 50 observed in the antibody array.   
Although there was no real difference in leptin levels on the antibody array (1.18 fold change 
from pre-differentiated to differentiated), literature suggests that leptin is playing a large part in the 
adipocyte secretome. To confirm whether leptin has a role, a more sensitive leptin ELISA was utilised 
with the two forms of ACM. The leptin ELISA showed that there was a considerable difference in the 
level of leptin between the two secretomes, differentiated ACM was quantified to have a concentration 
of 18pg/ml compared to the 1.7pg/ml in pre-differentiated, a fold change of 11 (Figure 15). 
Hepcidin, the laboratory’s main protein of interest, is hypothesised to be present in ACM but 
unfortunately was not present on the antibody array, so a specific hepcidin ELISA had to be utilised 
instead. Hepcidin was observed to be increased in differentiated ACM with a concentration of 
1782pg/ml compared the 994pg/ml in pre-differentiated ACM; giving a 1.8 fold change (Figure 15). 
Serum free media, used as a control, has previously been shown to contain 0pg/ml hepcidin, leptin or IL-
6. 
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Figure 15 - IL-6, Leptin and Hepcidin ELISAs – Leptin, IL-6 and hepcidin ELISAs were used to compare the 
levels of the three adipokines in serum-free media, pre-differentiated ACM and differentiated ACM. The 
graph shows the fold change from pre-differentiated ACM to differentiated ACM in IL-6, leptin and 
hepcidin levels. Serum-free media contained 0pg/ml of any of the adipokines. * represents statistical 
significance (p<0.05), as determined by a paired, two-tailed student T-test, comparing differentiated 
ACM to pre-differentiated ACM in that cell-line. n=3 with triplicate results in each n. 
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Effect of Leptin, IL-6 and Hepcidin on the viability and proliferation of CRC cell-lines 
To identify whether the three molecules analysed by ELISA were responsible for the increased viability 
and proliferation observed in RKO and SW480 cells with differentiated ACM, cells were treated with IL-6, 
leptin and hepcidin before viability and proliferation assays were carried out. All three molecules 
significantly increased the viability and proliferation of RKOs and SW480s (Figure 16), mirroring the 
effect observed when cells were treated with differentiated ACM. 
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Figure 16 - IL-6, Leptin and Hepcidin all increase the viability and proliferation of colorectal carcinoma 
cells – RKO and SW480s were stimulated with IL-6 (10ng/ml) , leptin (60ng/ml), hepcidin (1µM) or a no-
stim control for 24 hours before MTT and BrdU assays were performed (see materials and methods). 
Assays were quantified by changes in absorbance (at 450nm and 405nm for MTT and BrdU respectively). 
Mean data ±SEM is plotted with * representing statistical significance (p<0.05), determined by a paired, 
two-tailed student T-test, compared to the relevant no stim control in that cell-line. n=3 with triplicate 
results in each n. Treatment with IL-6, leptin and hepcidin significantly increased the proliferation and 
viability of RKO and SW480 cells compared to a media alone control. 
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To further establish whether these molecules were involved in responses observed in cell-lines when 
treated with differentiated ACM, cells were treated with ACM along with IL-6, leptin and hepcidin 
inhibitors/blockers. Treatment with the inhibitors reversed the increase in proliferation and viability 
observed when incubated with differentiated ACM alone (Figure 17). Proliferation of both cell-lines was 
returned to control (serum-free media) levels when treated with inhibitors/blockers of IL-6, leptin and 
hepcidin; whereas treatment with the inhibitors reduced cell viability below serum-free levels. 
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Figure 17 - Colorectal Carcinoma Cells treated with ACM and Leptin, IL-6 or Hepcidin Inhibitors – RKO and 
SW480s cells were treated with differentiated ACM alone or with leptin (3.2ng/ml), IL-6 (0.1ng/ml) or hepcidin 
(1µM) antagonists for 24 hours before MTT and BrdU assays were performed. Assays can be quantified by changes 
in absorbance (at 450nm and 405nm for MTT and BrdU respectively). Mean data ±SEM is plotted, with # 
representing statistical significance compared to the relevant serum-free media control and * representing 
statistical significance compared to treatment with differentiated ACM. Statistical significance is determined by a 
paired, two-tailed student T-test with p<0.05 being classified as significant. n=3 (except leptin block where n=2) 
with triplicate results in each n. Treatment of both cell-lines with ACM, lead to significant increases in both viability 
and proliferation compared to serum-free media control. However when treated with leptin, IL-6 and hepcidin 
inhibitors/blockers, the increased in proliferation and viability was reversed.   
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Leptin and IL-6 acting through hepcidin? 
To investigate whether any of the adipokines work through stimulating colorectal carcinoma cells to 
secrete other cytokines, the ELISAs were performed using secretomes of cells treated with leptin, IL-6 or 
hepcidin. After stimulation with an adipokine for 18 hours, all cells were washed thoroughly so any 
adipokine present was due to the cells secretion rather than leftover stimulation. As Figure 18A 
illustrates treatment with all three adipokines induced the cells to produce leptin and IL-6; even 
treatment with leptin and IL-6, induced a positive feedback situation with increased concentrations of 
the corresponding adipokine after treatment with it. Treating cells IL-6 and leptin also significantly 
induced hepcidin production compared to control (Figure 18); however treatment with hepcidin did not 
produce the positive feedback observed with the other adipokines. This suggests that perhaps the 
viability and proliferation observed through IL-6 and leptin stimulation, may act through hepcidin. To 
test this hypothesis, hepcidin expression levels were assessed through qRT-PCR, but unfortunately 
hepcidin was undetected in all samples; however the laboratory has previously had issues with the 
hepcidin probe therefore different methods were utilised to test this hypothesis.  
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Figure 18 – Leptin and IL-6 appear to work through Hepcidin – RKO and SW480 cells were stimulated 
with leptin (60ng/ml), IL-6 (10ng/ml), hepcidin (1µM) or a no-stim control for 24 hours. Cells were 
thoroughly washed before serum-free media added and the secretomes being collected 18 hours later. 
Secretomes from all treatments were then subjected leptin, IL-6 and hepcidin ELISAs.  (A) shows the 
different stimulation effects on secreted concentrations of leptin and IL-6  as determined by ELISAs. * 
represents statistical significance (p<0.05), as determined by a paired, two-tailed student T-test, 
compared to control of no stimulation. n=3 with triplicate results in each n. (B) shows how different 
stimulations affect secreted hepcidin concentrations as determined by ELISA. n=3 with triplicate results 
in each n. 
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To test the hypothesis that leptin and IL-6 may be acting through hepcidin, viability and proliferation 
assays were performed using Leptin and IL-6 stimulation but also the hepcidin antagonist peptide. In 
RKO cells, blocking hepcidin when treating with leptin, significantly decreased both viability and 
proliferation, compared to leptin stimulation alone, this was also observed with the proliferation of 
SW480s (Figure 19). When cells were treated with IL-6 and hepcidin was blocked there was evidence 
that viability and proliferation decreased in RKO cells, compared to IL-6 stimulated alone, this can also 
be observed with proliferation of SW480s. The results across cell lines, treatments and assays are not 
fully consistent, however, there is emerging evidence that leptin and IL-6 may be functioning through 
hepcidin. 
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Figure 19 - Blocking Hepcidin decreases proliferation with Leptin and IL-6 stimulation – RKO and 
SW480s were stimulated with IL-6 (10ng/ml), leptin (60ng/ml) or a no-stim control for 24 hours. Along 
with stimulation, half the samples were also treated with a hepcidin antagonist (1µM) for the 24 hours 
before MTT and BrdU assays were performed (see materials and methods). Assays can be quantified by 
changes in absorbance (at 450nm and 405nm for MTT and BrdU respectively). Mean data ±SEM is 
plotted with # representing statistical significance compared to the relevant no stim/no block control in 
that cell-line and * representing statistical significance with hepcidin block compared to the respective 
stimulation with no block. Statistical significance was determined by paired, two-tailed student T-tests 
with p<0.05 being determined significant. n=3 with triplicate results in each n. 
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A hepcidin reporter assay was performed to further assess leptin and IL-6 effect on its expression. The 
assay showed that IL-6 significantly increased hepcidin promoter activity in both cell-lines (Figure 20). 
Leptin significantly increased hepcidin expression in SW480 cells but had no effect in RKO cells. This 
supports the previous data suggesting both leptin and IL-6 may be functioning through hepcidin. 
 
 
Figure 20 – IL-6 induces Hepcidin expression – RKO and SW480 cells were transfected with PGL 
plasmids with (HEP) or without (PGL) hepcidin regulatory elements upstream from the firefly luciferase 
gene, for 24 hours. After transfection, cells were stimulated with leptin (60ng/ml), IL-6 (10ng/ml) or no 
stim control for 24 hours, before the dual luciferase reporter assay was carried out (see materials and 
methods). PGL provided a control of background luminescence as it did not contain hepcidin regulatory 
elements, data from HEP transfected cells was normalised to this to allow comparison between different 
stimulations. IL-6 significantly increased hepcidin expression in both cell-lines whereas leptin only 
significantly increased promoter activity in SW480s. The mean data ± SEM was plotted with * 
representing statistical significance (p<0.05), determined using a paired, two-tailed student T-test, 
compared with no stim control HEP in each cell-line. n=3 with duplicate results in each n. 
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Mechanism of increased viability and proliferation 
To establish exactly how cells become more viable and proliferative after incubation with differentiated 
ACM and stimulation with leptin, IL-6 and hepcidin, several different experiments were undertaken. Wnt 
signalling was initially assessed using a TOPFLASH assay, as increased signalling by this pathway may be 
responsible for the increased viability and proliferation observed. The TOPFLASH assay showed that 
both Leptin and IL-6 increased Wnt signalling in both cell-lines significantly (Figure 21). SW480s have 
more Wnt activity under normal conditions as they are APC null. The data suggested the adipokines may 
be inducing Wnt signalling in colon cancer cells, however even though the data is statistically significant, 
a larger fold change, particularly in the RKO cells, that contain WT APC, would be expected. 
 
Figure 21 - Adipokines increase Wnt signalling levels – RKO and SW480 cells were transfected with plasmids with 
WT (TOP) or mutated (FOP) Wnt signalling regulatory elements upstream from the firefly luciferase gene, for 24 
hours. After transfection, cells were stimulated with leptin (60ng/ml), IL-6 (10ng/ml) or no stim control for 24 
hours, before the dual luciferase reporter assay was carried out (see materials and methods). FOP provided a 
control of background luminescence as it did not contain Wnt signalling regulatory elements, data from TOP 
transfected cells was normalised to this to allow comparison between different stimulations. TOPFLASH assay 
shows treating cells with leptin and IL-6 increased Wnt signalling in both cell cell-lines but particularly in the APC 
null SW480 cells. The mean data ± SEM was plotted with * representing statistical significance (p<0.05), 
determined using a paired, two-tailed student T-test, compared with no stim control TOP in each cell-line. n=3 with 
duplicate results in each n. 
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To further assess this proposed mechanism, qRT-PCR for Lgr5 was performed, unfortunately no Lgr5 was 
detected in any of the samples; however the lack of Lgr5 presence in any of the samples is unusual, as 
constitutive expression would be expected in SW480 cells that have constitutive Wnt signalling - this 
suggested the Lgr5 primers/probe did not function properly. 
Myc and cyclin D1 expression were observed in the context of qRT-PCR. C-myc expression was 
upregulated compared to the control when both cell-lines were treated with ACM, particularly pre-
differentiated ACM (Figure 22). The same increase was not observed when cells were stimulated with 
leptin, hepcidin and IL-6, suggesting that these adipokines are not responsible for the increase in c-myc 
levels. The large increase in c-myc levels, when treated with pre-differentiated is to be expected, as pre-
differentiated ACM has been shown to contain increased insulin levels, which has in turn been shown to 
stimulate c-myc (Sun and Jin, 2008). Cyclin D1 levels decreased in RKOs when treated with differentiated 
ACM and leptin and IL-6 stimulations yet increased with the same treatments in SW480 cells. As the 
results are so varied and there is no apparent correlation, it would suggest cyclin D1 is not key 
contributor to the increased viability and proliferation.  
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Figure 22 - Adipokine and ACM Stimulation increase c-myc levels but has varying effects on Cyclin D1 
levels – RKO and SW480 cells were treated with leptin (60ng/ml), IL-6 (10ng/ml), hepcidin (1µM), pre-
differentiated ACM, differentiated ACM or no stim control for 24 hours. cDNA was generated from RNA 
extracted from cells and qRT-PCR carried out probing for myc and cyclin D1 (see materials and 
methods). The mean data ± SEM was plotted with * representing statistical significance (p<0.05), 
determined using a paired, two-tailed student T-test, compared with no stim control TOP in each cell-
line. n=3 with duplicate results in each n. 
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Discussion 
Adipocyte Conditioned Media 
Differentiated and pre-differentiated ACM were observed to be vastly different in this study, differing in 
both adipokines present and their effect on colorectal cancer cell-lines; these observed differences 
coincide with the literature and previous studies on the changes of adipokine secretome prior to and 
after adipogenesis (Zhong et al., 2010). Differentiated ACM had the most profound effect on colorectal 
cell lines, increasing both viability and proliferation significantly in both RKO and SW480 cells; compared 
to pre-differentiated ACM that increased viability but decreased proliferation. The most abundant 
adipokine in pre-differentiated ACM was insulin, however insulin has been shown to increase 
proliferation and viability of colorectal cells (Fenton and Birmingham, 2010), so the observed effects are 
likely to be induced by a factor, not detected in the adipokine array. 
As hypothesised, differentiated ACM was observed to accelerate colorectal cancer cell 
proliferation and viability. The differentiated ACM appeared to be, comparatively, more complex 
containing elevated levels of a diverse range of adipokines. IL-6 was the most abundant factor, and with 
obesity being more often described as a state of chronic inflammation, it is no surprise that IL-6, an 
inflammatory mediator, is present in such quantities. ENA-78, the second most abundant adipokine, 
according to the antibody array, has previously been shown to increase proliferation and migration in 
colorectal cancer cell-lines (Kawamura et al., 2011). Other adipokines found in the differentiated ACM 
have also been associated with increasing the proliferation of colon cells such as PAI-1 (plasminogen 
activator inhibitor-1) (Ho et al., 2012) and IL-8 (Ning and Lenz, 2012).  
The antibody array was useful as a quick assessment of whether a diverse range of molecules 
were present; however, they are not always specific enough to detect all molecules. In this study, the 
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antibody array detected very little leptin in differentiated ACM compared to pre-differentiated ACM, 
however when a leptin ELISA was utilised, a fold increase of 11 was actually observed. This illustrates 
the limitations of the array compared to the ELISA technique. Another limitation is that they may not 
contain antibodies for all the molecules of interest, for example in this study, hepcidin was an adipokine 
of primary interest, yet unfortunately was not array; however, utilisation of an ELISA specific for 
hepcidin confirmed its presence in the ACM. 
 
Leptin, IL-6 and Hepcidin 
Leptin, IL-6 and hepcidin were all confirmed by ELISA to be significantly elevated in differentiated ACM, 
compared to pre-differentiated ACM. When assessed as individual molecules, they all increased 
proliferation and viability of colorectal cancer cell-lines; yet when individually blocked in differentiated 
ACM, the increased proliferation and viability was reversed. The decrease in the viability and 
proliferation observed when the three adipokines were inhibited, compared to ACM treatment alone, 
shows how vital they are for the observed phenotype. The ELISA revealed that stimulation with leptin 
increased leptin, IL-6 and hepcidin levels in both cell-lines and likewise with IL-6 stimulation, suggesting 
the molecules are all individually important and capable of inducing cells, to secrete factors to further 
increase viability and proliferation. Leptin has previously been shown to induce IL-6 production in B cells 
(Agrawal et al., 2011) and IL-6 to induce leptin production in macrophages (Loffredal et al., 1998), while 
both have been shown to stimulate hepcidin (Chung et al., 2007)(Wrighting and Andrews, 2006). 
 
 
Hepcidin: a mediator? 
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Leptin and IL-6 stimulation increased the levels of hepcidin, as seen by ELISA, in colorectal cancer cell-
lines, although the results were not quite significant (p values= 0.056-0.180). These results suggested 
that the adipokines may be acting through hepcidin; to confirm this, hepcidin was blocked, as cells were 
stimulated with IL-6 and leptin with proliferation and viability being assessed. In RKO cells, proliferation 
and viability significantly decreased when cells were stimulated with leptin and hepcidin was blocked, as 
did the viability when stimulated with IL-6. Blocking hepcidin had no effect on the viability when SW480 
cells were stimulated with either leptin or IL-6, but proliferation was significantly decreased with both 
stimulations. The hepcidin reporter assay also showed that IL-6 increased hepcidin expression, with 
leptin only increasing hepcidin promoter activity in SW480s. Although the results are not fully 
consistent, there is a trend to suggest that hepcidin is important for the increased the viability and 
proliferation observed when cells are treated with IL-6 and leptin. This data coincides with current 
literature; Hintze et al. have previously described that IL-6 and leptin secreted from 3T3-L1, an adipocyte 
cell-line differentiated from murine fibroblasts, both induced hepcidin production in hepatocytes.  
 
Wnt Signalling 
The TOPFLASH reporter assay suggests that Wnt signalling is at least one of the mechanisms that 
adipokines leptin and IL-6 function through in colorectal cells; however, this mechanism cannot be 
confirmed without further study. Although the TOPFLASH assay data is significant, the laboratory have 
previously seen much larger increases in β-catenin promoter activity, when RKO and SW480s have been 
stimulated with leptin and IL-6; the smaller changes seen in this study, may be due to inefficient 
transfection resulting from technical issues with the transfection reagent. Repetition of this assay with a 
different transfection reagent would be appropriate to confirm the data.  
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Detection of Lgr5 by qRT-PCR would have provided an ideal method of assessing whether Wnt 
signalling is the pathway involved, but unfortunately technical difficulties rendered Lgr5 undetectable. 
Cyclin D1 and c-myc levels, both usually induced by Wnt signalling, were not significantly increased 
when cells were treated with differentiated ACM, suggesting this pathway might not be significantly 
involved. Literature, however, has previously described a role for Wnt signalling when colorectal cancer 
cells are stimulated with leptin, as cells with active Wnt signalling have been observed to have increased 
expression of the leptin receptor (Endo et al., 2011). 
 
Alternative Signalling Pathways 
Wnt signalling has been observed to have an important role in colorectal cells, with permutations in the 
pathway leading to deregulated proliferation and ultimately colorectal cancer. This study has suggested 
the Wnt signalling pathway may be involved in the effect ACM has on colorectal cancer cell-lines, 
however it is not the sole pathway, and other pathways must be involved. 
 Both IL-6 (Fenton and Birmingham, 2010) and leptin (Endo et al., 2011) have been associated 
with increasing STAT-3 phosphorylation and activation. Furthermore, in hepatocytes, IL-6 has been 
shown to induce hepcidin expression through STAT-3 (Wrighting and Andrews, 2006); this data coincides 
with some of the findings of this study and suggests that the JAK/STAT pathway may be a major 
contributor. Leptin has also been observed to activate other pathways including the MAPK pathway 
(Hardwick et al., 2001) and PI3K/Akt (Uddin et al., 2009) so these pathways may also have a role. Further 
work would be needed to elucidate whether any of the mentioned pathways are involved in increasing 
proliferation and viability of colorectal cancer cells, after treatment with adipokines. 
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Limitations and Further Work 
Although this investigation was a comprehensive study, there are obvious limitations. The largest flaw is 
the pooling of the ACM; although pooling decreases patient variability and gives an overall insight, it 
would not have been the preferred method. However, due to the limited availability of patient samples, 
it was the most applicable method of providing data. If samples were unlimited, it would have been 
preferable to compare fat samples by patient or pool, according to whether the patient was suffering 
from colorectal cancer or not. Comparing samples by patient BMI would also be an appropriate study. 
Another potential flaw is the stimulation of colorectal cells with leptin, IL-6 and hepcidin; although the 
cells were stimulated with concentrations of the adipokines widely used in the literature, these 
concentrations have proved to be much higher than the concentrations found in the ACM. Since levels 
of leptin, IL-6 and hepcidin in ACM have been quantified using ELISA, it would be appropriate to 
stimulate the cells with the concentrations secreted and further assess cell viability and proliferation. 
Unlimited samples would also have provided larger volumes of ACM; thus allowing ACM to be used 
directly in assays such as TOPFLASH and hepcidin reporters. 
 Mass spectrometry (MS) analysis of pre-differentiated and differentiated ACM to identify 
differences in the secreted factors, was originally one of the main aims of this study. It was planned also 
to use mass spectrometry to analyse secretomes from SW480 and RKOs treated with leptin, hepcidin 
and IL-6, to identify factors secreted that may be further promoting viability and proliferation. Methods 
were optimised and samples were prepared for the analysis; however due to technical issues, the 
analysis was unable to be completed. To further this work, it would be useful to utilise LC-MS/MS, as 
planned, to identify any differences between the two ACM and changes to the secretome of cell-lines 
after adipokine stimulation. 
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 To elucidate a pathway for the increased proliferation and viability there are several 
experiments that would be essential. To confirm, IL-6 and leptin are signalling through hepcidin, use of 
functioning hepcidin primers and probe are vital, as utilisation of qRT-PCR would quantify increased 
hepcidin expression in cells stimulated with IL-6, leptin and differentiated ACM. Wnt signalling could be 
re-assessed using a TOPFLASH assay with a different transfection reagent, to ensure efficient 
transfection, along with repeating the Lgr5 qRT-PCR with different primers/probe. Inhibition of Wnt 
signalling, using a GSK3 inhibitor, such as SB216763, or β-catenin knockdown using specific siRNA, with 
IL-6, leptin, hepcidin and ACM stimulation, would allow assessment of Wnt signalling’s involvement in 
the increased viability and proliferation observed. If Wnt signalling is determined to not be truly 
involved, other pathways would then need to be assessed to elucidate the mechanism of this increased 
proliferation and viability. 
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Appendices
 
Appendix 4 – The first 32 adipokines on the antibody array - The values are normalised to the density of pre-differentiated ACM, to allow easy 
comparison of the differences in the levels of adipokines between differentiated and pre-differentiated ACM. 
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Appendix 5 - The last 32 adipokines on the antibody array - The values are normalised to the density of pre-differentiated ACM, to allow easy 
comparison of the differences in the levels of adipokines between differentiated and pre-differentiated ACM. 
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